Lifemel Honey to Reduce Leucopenia During Chemotherapy

The U.S. National Library of Medicine website publicized the testing of LifeMel honey back in 2005.
This study eventually showed the efficacy of LifeMel, which can be ordered from Vitamin Global here: http://www.vitaminglobal.com/life-mel-honey-120g-tzuf-globus-ltd-p-1619-c-72.html  an excellent discount.

This study is not yet open for patient recruitment.
Verified by Rambam Health Care Campus October 2005

 Purpose

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

MedlinePlus related topics:  Breast Cancer
Genetics Home Reference related topics:  breast cancer

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures: 

• l Prevention of myelotoxicity-every week during chemotherapy.

Total Enrollment:  60

Study start: November 2005

 Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Criteria

Inclusion Criteria:

• l breast cancer patient treated with adjuvant chemotherapy
• l PS = 2 or less

Exclusion Criteria:

• l none

 Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00243165

Georgeta Fried, MD      972-4-8543018    mailto:g_fried@rambam.health.gov.il?subject=NCT00243165,%20LifemelCTIL:%20-%20%20Lifemel%20Honey%20to%20Reduce%20Leucopenia%20During%20Chemotherapy

Study chairs or principal investigators

Georgeta Fried, MD,  Principal Investigator,  Rambam Health Care Campus   

 More Information

Study ID Numbers:  LifemelCTIL
Last Updated:  October 20, 2005
Record first received:  October 20, 2005
ClinicalTrials.gov Identifier:  NCT00243165
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on August 10, 2007